Gilead Sciences (GILD) Stock Heads Up On COVID-19 Treatment Data

Gilead Sciences GILD Stock News

Gilead Sciences, Inc. (NASDAQ: GILD) is having a strong start to the trading session this morning, and for good reason. As the world looks for a way to tackle the severe symptoms of COVID-19, the company has released positive data surrounding a potential treatment. Here’s what’s happening:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

GILD Stock Climbs On Positive Results In Phase 3 COVID-19 Trial

In a press release, Gilead Sciences provided data from the Phase 3 SIMPLE trial. The trial is assessing 5-day and 10-day dosing durations durations of the antiviral remdesivir. The patients being provided with the treatment are hospitalized patients with severe manifestations of COVID-19.

The data released today that patients who received a 10-day treatment course of remdesivir showed similar improvement in clinical status when compared to those receiving a 5-day course. Importantly, no new safety signals were identified in either treatment group.

The results were promising from an efficacy standpoint as well. 50% of patients in the 5-day arm showed improvements after 11 days. In the 10-day arm, the 50% threshold was seen on day 10.

In a statement, Merdad Parsey, MD, PhD, CMO at GILD, had the following to offer:

Unlike traditional drug development, we are attempting to evaluate an investigational agent alongside an evolving global pandemic. Multiple concurrent studies are helping inform whether remdesivir is a safe and effective treatment for COVID-19 and how to best utilize the drug. These study results complement data from the placebo-controlled study of remdesivir conducted by the National Institute for Allergy and Infectious Diseases and help to determine the optimal duration of treatment with remdesivir. The study demonstrates the potential for some patients to be treated with a 5-day regimen, which could significantly expand the number of patients who could be treated with our current supply of remdesivir. This is particularly important in the setting of a pandemic, to help hospitals and healthcare workers treat more patients in urgent need of care.

This News Is Huge

The news released by Gilead Sciences is huge. At the end of the day, we are fighting a serious pandemic. In order to win this fight, we’re going to need vaccines, treatments, and adequate testing.

Testing is moving forward, multiple vaccines are already in preclinical and clinical trials, and when it comes to treatments, GILD announced a major breakthrough here. Should the data continue to be positive, this drug will likely be fast tracked, turning it into a huge revenue generating opportunity in the relatively near term.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.